跳至主要内容
临床试验/IRCT138712231764N1
IRCT138712231764N1已完成2 期

Effect of omega-3 fatty acids on the components of metabolic syndrome in schizophrenic, bipolar and schizoaffective patients taking olanzapine plus sodium valproate or olanzapine plus lithium.

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • psychiatric patients taking olanzapine plus sodium valproate or olanzapine plus lithium with clinical diagnosis of schizophrenia, bipolar mood disorder, schizoaffective disorder, ages between 18-60 yrs.
  • Exclusion criteria:
  • 1- Previous treatment with study drugs (olanzapine, sodium valproate, lithium) during the three months prior to trial initiation/participation,
  • 2- Having a significant active medical problem or abnormal lab tests before initiation of trial including:
  • Liver function tests= 3 normal ,
  • Thyroid stimulating hormone > 4.2 m.I.U/L,
  • GFR< 60 ml/min,
  • FBS> 125 mg/dl,
  • TG = 500 mg/dl ,
  • TG between 200-500 and Non-HDL cholesterol greater than or equal to 30+ target LDL: in cases of TG between 200-500, first Non-HDL cholesterol is calculated. Then the goal LDL of the patient is assessed according to NCEP ATP III LDL goals. Participants with TG between 200-500 are excluded if their Non-HDL cholesterol is greater than or equal to 30 + target LDL.
  • 3- Pregnancy and lactation
  • 4-Recent (within 4 weeks) consumption of omega 3 fatty acids
  • 5-BMI = 30
  • 6-Contraindications for the study drugs
  • 7-Patients or their family refusal to participation
  • 8-Taking Drugs much affecting study parameters.

排除标准

  • 未提供

研究者

相似试验